產(chǎn)品描述: | Acumapimod (BCT197) is an orally active p38 MAP kinase inhibitor, with an IC50 of less than 1 μM for p38α |
靶點: |
IC50: less than 1 μM (p38α);p38MAPK;Autophagy |
體外研究: |
Acumapimod is an inhibitor of p38α with an IC50 value of less than 1 μM. |
體內(nèi)研究: |
Acumapimod is an oral low-molecular-weight p38 inhibitor currently in development for the treatment of several inflammatory conditions, including chronic obstructive pulmonary disease (COPD). Intermittent short-term dosing of Acumapimod (75 mg on days 1 and 6) shows a marked improvement in lung function in COPD patients |
參考文獻: |
1. Norman P, et al. Investigational p38 inhibitors for the treatment of chronic obstructive pulmonary disease. Expert Opin Investig Drugs. 2015 Mar;24(3):383-92. 2. De Buck S, et al. Population PK-PD Model for Tolerance Evaluation to the p38 MAP Kinase Inhibitor BCT197. CPT Pharmacometrics Syst Pharmacol. 2015 Dec;4(12):691-700. |
溶解性: |
soluble in DMSO |
保存條件: |
-20℃ |
配置溶液濃度參考: |
|
1mg |
5mg |
10mg |
1 mM |
2.595 ml |
12.973 ml |
25.946 ml |
5 mM |
0.519 ml |
2.595 ml |
5.189 ml |
10 mM |
0.259 ml |
1.297 ml |
2.595 ml |
50 mM |
0.052 ml |
0.259 ml |
0.519 ml |
|
注意: |
部分產(chǎn)品我司僅能提供部分信息,我司不保證所提供信息的權(quán)威性,僅供客戶參考交流研究之用。 |